Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

ClinicalTrials.gov ID: NCT00006348

Public ClinicalTrials.gov record NCT00006348. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer. PURPOSE: This randomized phase III trial is studying how well ondansetron works compared to a placebo in treating patients with advanced cancer and chronic nausea and vomiting that is not caused by cancer therapy.

Study identification

NCT ID
NCT00006348
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
100 participants

Conditions and interventions

Eligibility (public fields only)

Age range
Not listed
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2000 (Type not available)
Primary completion
Sep 2001 (Actual)
Completion
Sep 2001 (Actual)
Last update posted
Jul 6, 2016

2000 – 2001

United States locations

U.S. sites
12
U.S. states
9
U.S. cities
12
Facility City State ZIP Site status
CCOP - Scottsdale Oncology Program Scottsdale Arizona 85259-5404 —
CCOP - Carle Cancer Center Urbana Illinois 61801 —
CCOP - Iowa Oncology Research Association Des Moines Iowa 50309-1016 —
Siouxland Hematology-Oncology Sioux City Iowa 51101-1733 —
CCOP - Wichita Wichita Kansas 67214-3882 —
Mayo Clinic Cancer Center Rochester Minnesota 55905 —
CCOP - Missouri Valley Cancer Consortium Omaha Nebraska 68131 —
Medcenter One Health System Bismarck North Dakota 58501 —
Altru Health Systems Grand Forks North Dakota 58201 —
CCOP - Toledo Community Hospital Oncology Program Toledo Ohio 43623-3456 —
Rapid City Regional Hospital Rapid City South Dakota 57709 —
CCOP - Sioux Community Cancer Consortium Sioux Falls South Dakota 57105-1080 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00006348, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 6, 2016 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00006348 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →